N
MDCO

Natixis’s Medicines Co MDCO Stock Holding History

Natixis’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,706
Closed -$377K – 1044
2017
Q1 		$377K Buy
+7,706
New +$351K ﹤0.01% 602

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Natixis's MDCO Position: Q2 2017 in Review

Natixis sold out of Medicines Co (MDCO) in Q2 2017, closing a stake of 7,706 shares — an estimated $377K sold.

Natixis first reported a position in MDCO in Q1 2017 and held it in 1 quarter. The position peaked at $377K in Q1 2017. 202 funds tracked by Wall St. Rank hold MDCO as of Q2 2017.

  • Natixis reported no remaining Medicines Co position as of Q2 2017 after selling out during the quarter.
  • Natixis sold 7,706 Medicines Co shares in Q2 2017, an estimated $377K.
  • Natixis first reported a position in Medicines Co in Q1 2017 and held it in 1 quarter.
  • Natixis's Medicines Co position peaked at $377K in Q1 2017.
  • 202 funds tracked by Wall St. Rank held Medicines Co as of Q2 2017.

Based on Natixis's 13F filing for Q2 2017, filed 14 Aug 2017.